New research published in New England Journal of Medicine and presented at this year's Annual Meeting of the European ...

Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

treat-to-target trial involving adults with type 2 diabetes who had not previously received insulin. Participants were randomly assigned in a 1:1 ratio to receive efsitora or degludec. The primary ...

and Xultophy (insulin degludec/liraglutide). That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine ...

Liraglutide was shown to rapidly improve insulin sensitivity as well as decrease blood glucose within two weeks of beginning treatment and before any weight loss. "GLP-1R agonists are an exciting ...

They can help you determine whether a different GLP-1 agonist medication like Ozempic, Victoza, or Trulicity ... 29 lb more than participants on insulin degludec 27 lb more than participants ...

It will compete with liraglutide and exenatide ... Medscape Medical News, January 24, 2013 Alert Long-Acting Insulin Degludec Approved in EU The European Commission has formally approved Novo ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical ...

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic ...

Two clinical trials compared the effectiveness of degludec (Tresiba), a longer-acting insulin which is taken at least once a day and delivers a steady stream of the medication during a 24-hour period, ...